Page 16 - Read Online
P. 16
Schaafsma et al. J Cancer Metastasis Treat 2021;7:34 https://dx.doi.org/10.20517/2394-4722.2021.72 Page 11 of 12
Conflicts of interest
All authors declared that there are no conflicts of interest.
Ethical approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Copyright
© The Author(s) 2021.
REFERENCES
1. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century.
J Clin Oncol 2010;28:2625-34. DOI PubMed PMC
2. Matthay KK, Maris JM, Schleiermacher G, et al. Neuroblastoma. Nat Rev Dis Primers 2016;2:16078. DOI PubMed
3. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010;362:2202-11. DOI PubMed PMC
4. Mossé YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature
2008;455:930-5. DOI PubMed PMC
5. Mosse YP, Laudenslager M, Khazi D, et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet 2004;75:727-
30. DOI PubMed PMC
6. Yan P, Qi F, Bian L, et al. Comparison of incidence and outcomes of neuroblastoma in children, adolescents, and adults in the United
States: a Surveillance, Epidemiology, and End Results (SEER) program population study. Med Sci Monit 2020;26:e927218. DOI
PubMed PMC
7. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64. DOI PubMed PMC
8. Yu AL, Gilman AL, Ozkaynak MF, et al; Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and
isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324-34. DOI PubMed PMC
9. Zhang P, Wu X, Basu M, et al. MYCN amplification is associated with repressed cellular immunity in neuroblastoma: an in silico
immunological analysis of TARGET database. Front Immunol 2017;8:1473. DOI PubMed PMC
10. Wei JS, Kuznetsov IB, Zhang S, et al. Clinically relevant cytotoxic immune cell signatures and clonal expansion of T-Cell receptors in
high-risk MYCN-not-amplified human neuroblastoma. Clin Cancer Res 2018;24:5673-84. DOI PubMed PMC
11. Layer JP, Kronmüller MT, Quast T, et al. Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic
neuroblastoma restraining interferon pathway activity and chemokine expression. Oncoimmunology 2017;6:e1320626. DOI PubMed
PMC
12. Zhong X, Zhang Y, Wang L, Zhang H, Liu H, Liu Y. Cellular components in tumor microenvironment of neuroblastoma and the
prognostic value. PeerJ 2019;7:e8017. DOI PubMed PMC
13. Westermann F, Muth D, Benner A, et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression
or malignant progression in neuroblastomas. Genome Biol 2008;9:R150. DOI PubMed PMC
14. Oberthuer A, Juraeva D, Li L, et al. Comparison of performance of one-color and two-color gene-expression analyses in predicting
clinical endpoints of neuroblastoma patients. Pharmacogenomics J 2010;10:258-66. DOI PubMed PMC
15. Henrich KO, Bender S, Saadati M, et al. Integrative genome-scale analysis identifies epigenetic mechanisms of transcriptional
deregulation in unfavorable neuroblastomas. Cancer Res 2016;76:5523-37. DOI PubMed
16. Munro SA, Lund SP, Pine PS, et al. Assessing technical performance in differential gene expression experiments with external spike-in
RNA control ratio mixtures. Nat Commun 2014;5:5125. DOI PubMed
17. Kocak H, Ackermann S, Hero B, et al. Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous
regression in neuroblastoma. Cell Death Dis 2013;4:e586. DOI PubMed PMC
18. Wang Q, Diskin S, Rappaport E, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that
multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 2006;66:6050-62. DOI PubMed
19. Rajbhandari P, Lopez G, Capdevila C, et al. Cross-cohort analysis identifies a TEAD4-MYCN positive feedback loop as the core
regulatory element of high-risk neuroblastoma. Cancer Discov 2018;8:582-99. DOI PubMed PMC
20. Łastowska M, Viprey V, Santibanez-Koref M, et al. Identification of candidate genes involved in neuroblastoma progression by
combining genomic and expression microarrays with survival data. Oncogene 2007;26:7432-44. DOI PubMed
21. Ackermann S, Cartolano M, Hero B, et al. A mechanistic classification of clinical phenotypes in neuroblastoma. Science
2018;362:1165-70. DOI PubMed PMC
22. Berwanger B, Hartmann O, Bergmann E, et al. Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage
neuroblastoma. Cancer Cell 2002;2:377-86. DOI PubMed
23. Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet 2013;45:279-84. DOI PubMed
PMC